28 February 2017 : Clinical Research
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus
Noriko Ihana-Sugiyama ABCDEF 1, Ritsuko Yamamoto-Honda ACDEF 1,2, Takehiro Sugiyama CDE 3, Tetsuro Tsujimoto D 1, Masafumi Kakei CDE 4, Mitsuhiko Noda ADE 5*DOI: 10.12659/MSMBR.902218
Med Sci Monit Basic Res 2017; 23:36-44
Supplementary Table 1. Continuous glucose monitoring profiles compared two test meals in the M+V group and the L group.
| 24-h average glucose levels (mg/dL) | AUC for 24-h glycemic fluctuation (mg·h/dL) | The SDs of the 24-h values (mg/dL) | Proportion of time (%) in hypoglycemia (<70 mg/dL) | Proportion of time (%) in hyperglycemia (>140 mg/dL) | Proportion of time (%) in hyperglycemia (>180 mg/dL) | MAGE | |
|---|---|---|---|---|---|---|---|
| Test meal | 120.3 (109.1–125.4) | 2887.8 (2616.9–3010.0) | 24.1 (21.6–58.8) | 2.1 (0.0–7.3) | 22.9 (19.8–25.3) | 0 (0.0–2.1) | 58.3 (52.3–60.0) |
| LC meal | 120.2 (114.0–120.4) | 2885.2 (27336.5–2890.0) | 37.5 (22.1–47.3) | 1.7 (0.0–17.0) | 33.3 (19.8–35.1) | 6.9 (6.6–8.3) | 77.0 (73.3–86.3) |
| value | 0.69 | 0.69 | 0.35 | 0.40 | 0.35 | 0.41 | 0.35 |
| Test meal | 129.1 (117.1–135.7) | 3101.0 (2805.1–3257.5) | 32.6 (16.6–52.7) | 0 (0.0–0.0) | 34.4 (21.9–47.6) | 17.0 (0–19.8) | 65.8 (47.7–91.8) |
| LC meal | 124.0 (121.4–129.1) | 2977.7 (2909.7–3094.9) | 30.6 (14.4–66.2) | 0 (0.0–2.1) | 25.0 (21.5–43.1) | 3.5 (0.0–21.9) | 103.0 (55.0–105.5) |
| value | 0.69 | 0.69 | 0.69 | 0.16 | 0.10 | 0.85 | 0.04 |
| (Median [minimum-maximum]). The CGM data of is reclassified by the M+V group and the L group to compare with two test meals. | |||||||